DENVER--(BUSINESS WIRE)--March 2, 2006--Myogen, Inc. (Nasdaq:MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) has been selected for presentation at ATS 2006 -- San Diego, the annual International Conference of the American Thoracic Society to be held May 19-24, 2006 at the San Diego Convention Center in San Diego, California.
